{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-060883","form_type":"8-K","ticker":null,"cik":"0001744659","company_name":"Akero Therapeutics, Inc.","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.370530+00:00","generated_at":"2026-06-05T02:47:37.906728+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Akero Therapeutics to raise ~$299M in public offering of 11M shares at $29.00/share","bullets":["Offering of 11,000,000 shares at $29.00 per share; underwriters have 30-day option for additional 1,650,000 shares.","Net proceeds expected ~$299.4M (or ~$344.4M if option exercised in full).","Proceeds to fund clinical development of efruxifermin (EFX) for NASH, including Phase 2b HARMONY and Phase 3 SYNCHRONY studies.","Cash runway extended into 2027; company currently has no agreements for acquisitions or investments with proceeds.","Offering expected to close March 8, 2024, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-060883","json":"https://secwatch.observer/filing/0001193125-24-060883.json","markdown":"https://secwatch.observer/filing/0001193125-24-060883.md","text":"https://secwatch.observer/filing/0001193125-24-060883.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1744659/000119312524060883/0001193125-24-060883-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1744659/000119312524060883/d808358d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T02:47:37.906728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a2fdef486f878cd1972c1fd6aa98ed1a9d9aaebf","claim":"Akero Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC, and Evercore Group L.L.C. valued at approximately $299.4 million (effective 2024-03-05).","evidence_excerpt":"On March 5, 2024, Akero Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC, and Evercore Group L.L.C. as representatives of the several underwriters named therein (the “ Underwriters ”) pursuant to which the Company agreed to issue and sell 11,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), to the Underwriters at a public offering price of $29.00 per share (the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1744659/000119312524060883/0001193125-24-060883-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC, and Evercore Group L.L.C."},{"label":"Value","value":"approximately $299.4 million"},{"label":"Effective","value":"2024-03-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}